Collaboration leverages cutting-edge digital platform to
streamline development and manufacturing activities and speed
patient access to life-changing treatments
LONDON and NEWARK,
N.J., April 24, 2024 /PRNewswire/ --
Autolomous, the market-leading
developer of critical manufacturing management
systems for cell and gene therapies, and BioCentriq,
industry-leading clinical-phase Cell Therapy CDMO (contract
development and manufacturing organization), announce a
collaboration to digitize and accelerate process development and
manufacturing activities.
Autolomous' autoloMATE® solution is an innovative,
no-code, fully cloud-native software platform designed to
materially affect the cell and gene therapy sector. Engineered with
precision for data capture, operational logistics, quality release
by exception, instantaneous tech transfer, and advanced data
analytics, autoloMATE offers unprecedented power and flexibility.
autoloMATE will equip BioCentriq with a pivotal tool to
significantly enhance efficiency while upholding the highest
standards of quality and data integrity in their groundbreaking
work.
BioCentriq will leverage the autoloMATE platform to streamline
its process development operations and enhance client experience,
utilizing its intuitive configuration and execution services. This
partnership aims to ultimately accelerate batch delivery, ensuring
patients have faster access to cutting-edge cell therapies.
"Autolomous' autoloMATE platform will transform our operations,
replacing paper-based systems with a purpose-built digital
solution," said David Smith, Ph.D.,
Vice President of Development at BioCentriq. "By streamlining data
exchange throughout the development and manufacturing processes, we
will be able to enhance operational efficiency and flexibility,
de-risk timelines and ultimately deliver life-changing therapies to
patients more quickly."
"BioCentriq's unwavering dedication to pioneering new paths in
the medical field, coupled with their spirit of collaboration,
perfectly aligns with our vision," said Alexander Seyf, CEO and
Co-founder of Autolomous. "The distinct capabilities of our
platform are meticulously engineered to navigate and surmount the
intricacies of cell and gene therapy development and production.
Through our partnership, we are poised to accelerate towards a
future where life-saving therapies are within reach of every
patient in need, marking a significant leap forward in healthcare
innovation."
About BioCentriq
BioCentriq is an experienced and
highly collaborative clinical-phase cell therapy CDMO. The company
has been successfully developing, manufacturing, and releasing GMP
drug product for use in clinical trials since 2022. With
industry-recognized leadership, scientists, engineers, analysts,
and manufacturing specialists, along with established quality
systems and modern infrastructure, BioCentriq is a trusted
strategic partner for the development and manufacture of both
autologous and allogeneic cell therapies. In June 2023, BioCentriq launched its
LEAP™ Advanced Therapy Platform, designed to help cell therapy
developers move from contract to clinic in as little as six months.
The company was purchased by GC of South
Korea for $73 million in
May 2022. To learn more visit
www.biocentriq.com.
For more information contact:
David Smith
david.smith@biocentriq.com
About Autolomous
Autolomous LTD stands at the
forefront of innovation, revolutionizing the manufacturing
management systems for the burgeoning cell and gene therapy market.
With a global reach, our suite of fully integrated, digitized, and
automated solutions leverages cutting-edge advancements such as
Ledger technology, the Internet of Things (IoT), and AI. This
strategic integration not only ensures adherence to stringent
regulatory standards, both present and future, but also paves the
way for manufacturers to streamline operations, cut costs, and
extend these life-saving therapies to an ever-growing number of
patients.
Our flagship platform, autoloMATE®, embodies a critical,
robust digital framework that enhances efficiency, scalability, and
process optimization in the production and release of cell and gene
therapies. Validated within the rigorous confines of GxP highly
regulated environments, autoloMATE is currently deployed in both
non-GMP and GMP production settings.
Rooted in London, Autolomous was
brought to life in 2019 by a team of seasoned professionals whose
expertise spans advanced therapies, medical practice, and
enterprise-level technology, software, and business. To discover
more about how Autolomous, visit www.autolomous.com.
For more information contact:
Alexander Seyf
alexander@autolomous.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/autolomous-and-biocentriq-partner-to-speed-up-cell-therapy-delivery-302126536.html
SOURCE BioCentriq Inc.